The conversation is about the order of applying hair loss treatments, specifically The Ordinary serum and Zix. The user is unsure which to apply first due to the alcohol content in Zix.
The user has been using topical finasteride and minoxidil since 2021 and is exploring other hair treatment companies like Xyon and Happy Head due to dissatisfaction with the current product's smell. They question the authenticity of consultations from these companies, suspecting they might be automated.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
Musely sells a hair topical solution containing latanoprost, which degrades in 6 weeks, yet they market it as a 3-month supply. Concerns are raised about the product's effectiveness and the company's sales strategy.
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.
Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.
The conversation humorously discusses hair loss treatments, specifically mentioning microneedling, Minoxidil, finasteride, and RU58841. Users joke about using a new microneedling tool to combat hair loss.
The conversation humorously discusses using a full head wig for hair, beard, and perfect skin, with mentions of treatments like finasteride, RU58841, and microneedling. It highlights a shift from serious hair loss discussions to satire and memes.
The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.
Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.
RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.
The post and conversation are about skepticism towards HairClone's crowdfunding campaign for a hair loss cure, with users expressing doubt and calling it a scam. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.
The conversation discusses exploring new hair loss treatments beyond popular ones like Finasteride, Minoxidil, and Ketoconazole. Specific treatments mentioned include ozone therapy, Dutasteride mesotherapy, RegeneraActiva, microcurrent electrical hair stimulation, Nourkrin, and BioEqua Enercharger.
The conversation discusses hair loss and the ineffectiveness of a treatment called pyrilutamide, with one user experiencing negative results and questioning the product's authenticity.
The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.
An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.
A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
A person is experimenting with microneedling on one temple while using Minoxidil to address hair loss. They plan to needle weekly and apply Minoxidil twice daily, avoiding application around needling sessions.